Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma

Intervirology

Volumn 51, Issue SUPPL. 1, 2008, Pages 42-45

  Sakamoto, Michiie ^a   Mori, Taisuke ^a   Masugi, Yohei ^a   Effendi, Kathryn ^a   Rie, Irie ^a   Du, Wenlin ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CAP2; Early hepatocellular carcinoma; Expression profile; HSP70; Molecular markers; Precancerous lesions

Indexed keywords

ALPHA FETOPROTEIN; CYCLASE ASSOCIATED PROTEIN 2; GLUTAMATE AMMONIA LIGASE; GLYPICAN 3; HEAT SHOCK PROTEIN 70; TUMOR MARKER;

CONFERENCE PAPER; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BIOPSY; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; GLUTAMATE-AMMONIA LIGASE; GLYPICANS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MEMBRANE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 44949120637     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000122603     Document Type: Conference Paper

References (20)

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532.
2. Arakawa M, Kage M, Sugihara S, Nakashima T, Suenaga M, Okuda K: Emergence of malignant lesions within an adenomatous hyperplastic nodule in a cirrhotic liver. Observations in five cases. Gastroenterology 1986;91:198-208.
3. Tsuda H, Hirohashi S, Shimamoto Y, Terada M, Hasegawa H: Clonal origin of atypical adenomatous hyperplasia of the liver and clonal identity with hepatocellular carcinoma. Gastroenterology 1988;95:1664-1666.
4. Takayama T, Makuuchi M, Hirohashi S, Sakaomoto M, Okazaki N, Takayasu K, Kosuge T, Motoo Y, Yamazaki S, Hasegawa H: Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990;336:1150-1153.
5. Sakamoto M, Hirohashi S, Shimamoto Y: Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991;22:172-178.
6. Hirohashi S, Ishak KG, Kojiro M, Puig PL, Wanless IR, Fischer HP, Theise ND, Sakamoto M, Tsukuma H: Hepatocellular carcinoma; in Hamilton SR, Aaltonen LA (eds): Pathology and Genetics of Tumors of the Digestive System. Lyon, IARC Press, 2000, pp 159-172.
7. Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, Unoura M, et al: Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991;178:493-497.
8. Kudo M: Morphological diagnosis of hepatocellular carcinoma: special emphasis on intranodular hemodynamic imaging. Hepatogastroenterology 1998;45(suppl 3):1226-1231.
9. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Ymamoto J, Shimada K, Kosuge T, Okada S, Takayasu K, Yamasaki S: Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998;28:1241-1246.
10. Sakamoto M, Hirohashi S: Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jpn J Clin Oncol 1998;28:604-608.
11. Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, Hirohashi S: Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003;37:198-207.
12. Shibata R, Mori T, Du W, Chuma M, Gotoh M, Shimazu M, Ueda M, Hirohashi S, Sakamoto M: Overexpression of cyclase-associated protein 2 in multistage hepatocarcinogenesis. Clin Cancer Res 2006;12:5363-5368.
13. Fedor-Chaiken M, Deschenes RJ, Broach JR: SRV2, a gene required for RAS activation of adenylate cyclase in yeast. Cell 1990;61:329-340.
14. Baum B, Li W, Perrimon N: A cyclase-associated protein regulates actin and cell polarity during Drosophila oogenesis and in yeast. Curr Biol 2000;10:964-973.
15. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J: Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
16. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y: Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25.
17. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K, Nezu J, Tsunoda H, Yoshino T, Ohizumi I, Tsuchiya M, Ohnishi S, Makuuchi M, Hamakubo T, Kodama T, Aburatani H: Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-2423.
18. Osada T, Sakamoto M, Nagawa H, Yamamoto J, Matsuno Y, Iwamatsu A, Muto T, Hirohashi S: Acquisition of glutamine synthetase expression in human hepatocarcinogenesis: relation to disease recurrence and possible regulation by ubiquitin-dependent proteolysis. Cancer 1999;85:819-831.
19. Cadoret A, Ovejero C, Terris B, Souil E, Lévy L, Lamers WH, Kitajewski J, Kahn A, Perret C: New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 2002;21:8293-8301.
20. Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, Montorsi M, Torzilli G, Tommasini M, Terracciano L, Tornillo L, Vecchione R, Roncalli M: Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007;45:725-734.